

# Alfred Kim

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9131754/alfred-kim-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65  
papers

2,284  
citations

25  
h-index

47  
g-index

78  
ext. papers

3,346  
ext. citations

7.2  
avg. IF

5.68  
L-index

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 65 | Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. <i>Nature Medicine</i> , <b>2021</b> , 27, 717-726  | 50.5 | 497       |
| 64 | The complement system in COVID-19: friend and foe?. <i>JCI Insight</i> , <b>2020</b> , 5,  | 9.9  | 168       |
| 63 | IL-15 enhances survival and function of HIV-specific CD8+ T cells. <i>Blood</i> , <b>2003</b> , 101, 1024-9  | 2.2  | 111       |
| 62 | Chikungunya viral arthritis in the United States: a mimic of seronegative rheumatoid arthritis. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 1214-1220  | 9.5  | 98        |
| 61 | Rac1 activation in podocytes induces rapid foot process effacement and proteinuria. <i>Molecular and Cellular Biology</i> , <b>2013</b> , 33, 4755-64  | 4.8  | 89        |
| 60 | Complement C5a receptor is essential for the optimal generation of antiviral CD8+ T cell responses. <i>Journal of Immunology</i> , <b>2004</b> , 173, 2524-9   | 5.3  | 86        |
| 59 | Cardiac manifestations of systemic lupus erythematosus. <i>Rheumatic Disease Clinics of North America</i> , <b>2014</b> , 40, 51-60  | 2.4  | 81        |
| 58 | Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 1572-1585                         | 8    | 80        |
| 57 | Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. <i>Science Immunology</i> , <b>2021</b> , 6,  | 28   | 66        |
| 56 | Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1386-1388     | 2.4  | 56        |
| 55 | Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2 <b>2021</b> ,   |      | 44        |
| 54 | Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 659-666                         | 5.1  | 40        |
| 53 | SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies <b>2021</b> ,   |      | 39        |
| 52 | Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>RMD Open</i> , <b>2021</b> , 7,           | 5.9  | 36        |
| 51 | Cell depletion in mice that express diphtheria toxin receptor under the control of SiglecH encompasses more than plasmacytoid dendritic cells. <i>Journal of Immunology</i> , <b>2014</b> , 192, 4409-16 | 5.3  | 35        |
| 50 | Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 36-47  | 9.5  | 34        |
| 49 | Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , <b>2021</b> , 102927                                     | 13.6 | 34        |

|    |  |      |    |
|----|--|------|----|
| 48 | Alveolar macrophage development in mice requires L-plastin for cellular localization in alveoli. <i>Blood</i> , <b>2016</b> , 128, 2785-2796   | 2.2  | 33 |
| 47 | Macrophages modulate cardiac function in lipotoxic cardiomyopathy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2012</b> , 303, H1366-73  | 5.2  | 32 |
| 46 | B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement. <i>JCI Insight</i> , <b>2017</b> , 2,   | 9.9  | 32 |
| 45 | : hydroxychloroquine, COVID-19 and the role of the rheumatologist. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 734-736   | 2.4  | 32 |
| 44 | From mechanism to therapies in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , <b>2017</b> , 29, 178-186  | 5.3  | 28 |
| 43 | Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 420-430  | 9.5  | 25 |
| 42 | Novel mechanism of tumor suppression by polarity gene discs large 1 (DLG1) revealed in a murine model of pediatric B-ALL. <i>Cancer Immunology Research</i> , <b>2013</b> , 1, 426-37  | 12.5 | 21 |
| 41 | SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Disease: A Systematic Literature Review And Meta-Analysis. <i>Arthritis and Rheumatology</i> , <b>2021</b> ,   | 9.5  | 20 |
| 40 | Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 1185-1204  | 5.1  | 18 |
| 39 | The interplay between neutrophils, complement, and microthrombi in COVID-19. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2021</b> , 35, 101661   | 5.3  | 18 |
| 38 | Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection <b>2021</b> ,  |      | 16 |
| 37 | Barriers to and Facilitators of a Career as a Physician-Scientist Among Rheumatologists in the US. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 1191-1201  | 4.7  | 12 |
| 36 | Neutrophils promote VLA-4-dependent B cell antigen presentation and accumulation within the meninges during neuroinflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 24221-24230   | 11.5 | 12 |
| 35 | Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology</i> , <b>2021</b> , 3, e707-e714  | 14.2 | 11 |
| 34 | Barriers and Facilitators of Mentoring for Trainees and Early Career Investigators in Rheumatology Research: Current State, Identification of Needs, and Road Map to an Inter-Institutional Adult Rheumatology Mentoring Program. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 445-453 | 4.7  | 9  |
| 33 | New roles revealed for T cells and DCs in glomerulonephritis. <i>Journal of Clinical Investigation</i> , <b>2009</b> , 119, 1074-6   | 15.9 | 9  |
| 32 | COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations.. <i>Nature Reviews Rheumatology</i> , <b>2022</b> ,   | 8.1  | 9  |
| 31 | Preparation of 9,9-dimethoxytetracyclo[8.5.0.02,8.07,11]pentadeca-3,5,12,14,-tetraene and conversion to hexacyclo[8.5.1.14,7.05,14.06,12.011,15.016,17]heptadeca-2,8-diene-13-one using a domino Diels-Alder reaction. <i>Tetrahedron</i> , <b>1998</b> , 54, 7013-7024                          | 2.4  | 8  |

|    |   |      |   |
|----|---|------|---|
| 30 | Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving Tumor Necrosis Factor- $\alpha$ inhibitors. <i>Med</i> , <b>2021</b> ,                      | 31.7 | 8 |
| 29 | "Not Having the Real Support That We Need": Patients' Experiences with Ambiguity of Systemic Lupus Erythematosus and Erosion of Social Support. <i>ACR Open Rheumatology</i> , <b>2019</b> , 1, 135-144       | 3.5  | 6 |
| 28 | Development and Optimization of an ELISA to Quantitate C3(H <sub>2</sub> O) as a Marker of Human Disease. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 703  | 8.4  | 6 |
| 27 | Choroidal thickness in lupus nephritis. <i>Lupus</i> , <b>2020</b> , 29, 205-209  | 2.6  | 5 |
| 26 | COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.. <i>Lancet Rheumatology</i> , <b>2022</b> ,   | 14.2 | 4 |
| 25 | Web Exclusive. Annals On Call - COVID-19: Is Chloroquine the Answer?. <i>Annals of Internal Medicine</i> , <b>2020</b> , 172, OC1   | 8    | 4 |
| 24 | Response to: "Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?" by Erre. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,                       | 2.4  | 4 |
| 23 | The beneficial and pathogenic roles of complement in COVID-19. <i>Cleveland Clinic Journal of Medicine</i> , <b>2020</b> ,  | 2.8  | 3 |
| 22 | A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic. <i>ACR Open Rheumatology</i> , <b>2020</b> , 2, 491-495      | 3.5  | 3 |
| 21 | Patient Perspective on Using Digital Resources to Address Unmet Needs in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1568-1576                                       | 4.7  | 3 |
| 20 | Inflammatory arthritis in patients with COVID-19. <i>Translational Research</i> , <b>2021</b> , 232, 49-59  | 11   | 3 |
| 19 | New approaches in renal microscopy: volumetric imaging and superresolution microscopy. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2016</b> , 25, 159-67                                       | 3.5  | 3 |
| 18 | Exploring intentional medication non-adherence in patients with systemic lupus erythematosus: the role of physician-patient interactions. <i>Rheumatology Advances in Practice</i> , <b>2021</b> , 5, rkaa078 | 1.1  | 3 |
| 17 | Response to: "Case series of acute arthritis in COVID-19 admission" by López-González. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,  | 2.4  | 2 |
| 16 | Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2021</b> , 35, 101658           | 5.3  | 2 |
| 15 | The contribution of the observational research design to COVID-19 research. <i>Lancet Rheumatology</i> , <b>2020</b> , 2, e650-e652   | 14.2 | 1 |
| 14 | Response to: "Correspondence on hydroxychloroquine, COVID-19 and the role of the rheumatologist" by Graef by Lo. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,                                      | 2.4  | 1 |
| 13 | Cognitive dysfunction among people with systemic lupus erythematosus is associated with reduced participation in daily life. <i>Lupus</i> , <b>2021</b> , 30, 1100-1107                                       | 2.6  | 1 |

|    |   |      |   |
|----|---|------|---|
| 12 | Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving TNF- $\alpha$ inhibitors  |      | 1 |
| 11 | Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases. <i>Current Opinion in Pharmacology</i> , <b>2022</b> , 102243                                    | 5.1  | 1 |
| 10 | Belimumab for systemic lupus erythematosus - Focus on lupus nephritis.. <i>Human Vaccines and Immunotherapeutics</i> , <b>2022</b> , 2072143  | 4.4  | 1 |
| 9  | Development of a digital toolkit to improve quality of life of patients with systemic lupus erythematosus. <i>Digital Health</i> , <b>2021</b> , 7, 20552076211033423   | 4    | 0 |
| 8  | B cells: more than just for antibodies in SARS-CoV-2 vaccine responses. <i>Lancet Rheumatology</i> , <b>2021</b> , 3, e741-e743   | 14.2 | 0 |
| 7  | Reply. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1590-1592  | 9.5  |   |
| 6  | Measures of Sleep in Rheumatologic Diseases: Sleep Quality Patient-Reported Outcomes in Rheumatologic Diseases. <i>Arthritis Care and Research</i> , <b>2020</b> , 72 Suppl 10, 410-430   | 4.7  |   |
| 5  | Response to: Emergency arising from patients'fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?Tby Santos-Moreno. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , | 2.4  |   |
| 4  | Response to: Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritisTby Singer. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,   | 2.4  |   |
| 3  | Cognitive Domains Related to Participation among People with Systematic Lupus Erythematosus. <i>Archives of Physical Medicine and Rehabilitation</i> , <b>2020</b> , 101, e100-e101   | 2.8  |   |
| 2  | Reply to Ttaking a stand against the politicization of medical research: how "swinging the pendulum" poses a hazard to clinical trials, study participants, and the progress of scienceT <i>Expert Review of Clinical Immunology</i> , <b>2021</b> , 17, 105-107  | 5.1  |   |
| 1  | Patient-Reported Outcomes in SLE <b>2021</b> , 213-227  |      |   |